Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 211 | 4.270 |
Why?
|
| Rhinitis | 12 | 2023 | 185 | 3.750 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 68 | 1.710 |
Why?
|
| Nasal Polyps | 6 | 2023 | 71 | 1.380 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 138 | 1.220 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 62 | 1.190 |
Why?
|
| Endoscopy | 9 | 2023 | 199 | 1.020 |
Why?
|
| Chronic Disease | 11 | 2023 | 534 | 0.880 |
Why?
|
| Betacoronavirus | 5 | 2020 | 89 | 0.800 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 17 | 0.780 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 101 | 0.760 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 104 | 0.760 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 15 | 0.690 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 234 | 0.630 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 17 | 0.620 |
Why?
|
| Neutrophils | 1 | 2018 | 120 | 0.590 |
Why?
|
| Otolaryngology | 4 | 2021 | 34 | 0.580 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.570 |
Why?
|
| Aspergillosis | 1 | 2017 | 12 | 0.570 |
Why?
|
| Mucormycosis | 1 | 2017 | 9 | 0.570 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.570 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3665 | 0.560 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 42 | 0.550 |
Why?
|
| Humans | 34 | 2023 | 31070 | 0.530 |
Why?
|
| Middle Aged | 15 | 2023 | 10239 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 33 | 0.380 |
Why?
|
| Adult | 11 | 2023 | 8949 | 0.350 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 37 | 0.350 |
Why?
|
| Simulation Training | 2 | 2020 | 43 | 0.340 |
Why?
|
| Nose | 2 | 2021 | 43 | 0.330 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 26 | 0.290 |
Why?
|
| Male | 14 | 2021 | 16499 | 0.290 |
Why?
|
| Female | 14 | 2021 | 17018 | 0.290 |
Why?
|
| Internship and Residency | 2 | 2021 | 227 | 0.280 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 74 | 0.260 |
Why?
|
| Aged | 10 | 2023 | 10079 | 0.250 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 9 | 0.250 |
Why?
|
| Skull Base | 2 | 2023 | 32 | 0.250 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1133 | 0.220 |
Why?
|
| Inflammation | 3 | 2023 | 362 | 0.220 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 14 | 0.220 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 17 | 0.220 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 57 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 67 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2021 | 54 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 99 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 150 | 0.190 |
Why?
|
| Air Pollution | 1 | 2021 | 18 | 0.190 |
Why?
|
| Professional Role | 1 | 2021 | 30 | 0.190 |
Why?
|
| Air Pollutants | 1 | 2021 | 13 | 0.190 |
Why?
|
| Pandemics | 5 | 2020 | 274 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 6 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 54 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 4 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 73 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3809 | 0.180 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 9 | 0.180 |
Why?
|
| Child | 2 | 2022 | 1431 | 0.180 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2020 | 7 | 0.180 |
Why?
|
| Epistaxis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 9 | 0.180 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 12 | 0.180 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 19 | 0.180 |
Why?
|
| Urban Health Services | 1 | 2020 | 14 | 0.180 |
Why?
|
| Smell | 1 | 2020 | 19 | 0.180 |
Why?
|
| Airway Management | 1 | 2020 | 17 | 0.180 |
Why?
|
| Tracheostomy | 1 | 2020 | 26 | 0.180 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.180 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 387 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 80 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 25 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 32 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2019 | 6 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 144 | 0.170 |
Why?
|
| Surgeons | 1 | 2021 | 87 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2019 | 12 | 0.170 |
Why?
|
| Carcinoma | 1 | 2020 | 64 | 0.170 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 30 | 0.170 |
Why?
|
| Preoperative Care | 1 | 2020 | 144 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 818 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 66 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 126 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.160 |
Why?
|
| Fibrosis | 1 | 2018 | 39 | 0.160 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 408 | 0.160 |
Why?
|
| Wound Healing | 1 | 2019 | 174 | 0.160 |
Why?
|
| Phenotype | 1 | 2019 | 379 | 0.160 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 149 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 112 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 241 | 0.150 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.150 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.150 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.150 |
Why?
|
| Young Adult | 3 | 2020 | 2063 | 0.150 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 8 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 50 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 230 | 0.140 |
Why?
|
| Acute Disease | 1 | 2017 | 232 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 586 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5192 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 997 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 237 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 924 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1898 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2021 | 69 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 322 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 404 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 354 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 407 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 943 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2593 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 2403 | 0.060 |
Why?
|
| Encephalocele | 1 | 2023 | 32 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 35 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 49 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 12 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 13 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 663 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 40 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 6 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 25 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 36 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 17 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 190 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 24 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 5 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 22 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 370 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 27 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 410 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 29 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 37 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 45 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 95 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 85 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 55 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 68 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 41 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 58 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 27 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 57 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 186 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 335 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 260 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 500 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 246 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 197 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 50 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 818 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 310 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 874 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 1681 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 380 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2375 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_